307 related articles for article (PubMed ID: 10330150)
1. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans.
Cruz MC; Cavallo LM; Görlach JM; Cox G; Perfect JR; Cardenas ME; Heitman J
Mol Cell Biol; 1999 Jun; 19(6):4101-12. PubMed ID: 10330150
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR.
Cruz MC; Goldstein AL; Blankenship J; Del Poeta M; Perfect JR; McCusker JH; Bennani YL; Cardenas ME; Heitman J
Antimicrob Agents Chemother; 2001 Nov; 45(11):3162-70. PubMed ID: 11600372
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.
Bastidas RJ; Shertz CA; Lee SC; Heitman J; Cardenas ME
Eukaryot Cell; 2012 Mar; 11(3):270-81. PubMed ID: 22210828
[TBL] [Abstract][Full Text] [Related]
4. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans.
Arndt C; Cruz MC; Cardenas ME; Heitman J
Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():1989-2000. PubMed ID: 10463165
[TBL] [Abstract][Full Text] [Related]
5. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
Lorenz MC; Heitman J
J Biol Chem; 1995 Nov; 270(46):27531-7. PubMed ID: 7499212
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin is required for virulence of Cryptococcus neoformans.
Odom A; Muir S; Lim E; Toffaletti DL; Perfect J; Heitman J
EMBO J; 1997 May; 16(10):2576-89. PubMed ID: 9184205
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.
Alarcon CM; Heitman J; Cardenas ME
Mol Biol Cell; 1999 Aug; 10(8):2531-46. PubMed ID: 10436010
[TBL] [Abstract][Full Text] [Related]
8. The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine.
Weisman R; Choder M
J Biol Chem; 2001 Mar; 276(10):7027-32. PubMed ID: 11096119
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein.
Odom A; Del Poeta M; Perfect J; Heitman J
Antimicrob Agents Chemother; 1997 Jan; 41(1):156-61. PubMed ID: 8980772
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
Del Poeta M; Cruz MC; Cardenas ME; Perfect JR; Heitman J
Antimicrob Agents Chemother; 2000 Mar; 44(3):739-46. PubMed ID: 10681348
[TBL] [Abstract][Full Text] [Related]
11. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.
Stan R; McLaughlin MM; Cafferkey R; Johnson RK; Rosenberg M; Livi GP
J Biol Chem; 1994 Dec; 269(51):32027-30. PubMed ID: 7528205
[TBL] [Abstract][Full Text] [Related]
12. TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals.
Cutler NS; Heitman J; Cardenas ME
Mol Cell Endocrinol; 1999 Sep; 155(1-2):135-42. PubMed ID: 10580846
[TBL] [Abstract][Full Text] [Related]
13. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
Cafferkey R; Young PR; McLaughlin MM; Bergsma DJ; Koltin Y; Sathe GM; Faucette L; Eng WK; Johnson RK; Livi GP
Mol Cell Biol; 1993 Oct; 13(10):6012-23. PubMed ID: 8413204
[TBL] [Abstract][Full Text] [Related]
14. Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.
Alarcon CM; Cardenas ME; Heitman J
Genes Dev; 1996 Feb; 10(3):279-88. PubMed ID: 8595879
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and rapamycin.
Xu Q; Liang S; Kudla J; Luan S
Plant J; 1998 Aug; 15(4):511-9. PubMed ID: 9753776
[TBL] [Abstract][Full Text] [Related]
16. Missense mutations at the FKBP12-rapamycin-binding site of TOR1.
Freeman K; Livi GP
Gene; 1996 Jun; 172(1):143-7. PubMed ID: 8654975
[TBL] [Abstract][Full Text] [Related]
17. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
Sabatini DM; Erdjument-Bromage H; Lui M; Tempst P; Snyder SH
Cell; 1994 Jul; 78(1):35-43. PubMed ID: 7518356
[TBL] [Abstract][Full Text] [Related]
18. Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase.
Dolinski KJ; Heitman J
Genetics; 1999 Mar; 151(3):935-44. PubMed ID: 10049913
[TBL] [Abstract][Full Text] [Related]
19. FAP1, a homologue of human transcription factor NF-X1, competes with rapamycin for binding to FKBP12 in yeast.
Kunz J; Loeschmann A; Deuter-Reinhard M; Hall MN
Mol Microbiol; 2000 Sep; 37(6):1480-93. PubMed ID: 10998178
[TBL] [Abstract][Full Text] [Related]
20. Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit
Hoy MJ; Park E; Lee H; Lim WY; Cole DC; DeBouver ND; Bobay BG; Pierce PG; Fox D; Ciofani M; Juvvadi PR; Steinbach W; Hong J; Heitman J
mBio; 2022 Jun; 13(3):e0104922. PubMed ID: 35604094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
